Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors (AID)
Anti-Inflammatory Dietary Intervention in Breast Cancer Patients Receiving Aromatase Inhibitors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Belgrade, Serbia, 11129
- Recruiting
- Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade
-
Contact:
- Vesna Vucic, PhD
- Phone Number: +381113031997
- Email: vesna.vucic.imr@gmail.com
-
Contact:
- Danijela Ristic Medic, MD PhD
-
Principal Investigator:
- Vesna Vucic, PhD
-
Belgrade, Serbia, 11070
- Recruiting
- Clinical Hospital Center Bezanijska Kosa
-
Contact:
- Nebojsa Ivanovic, Dr
- Phone Number: 0603947871
- Email: ivanovicnebojsadr@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 45 to 70 years
- Postmenopausal women
- Histologically confirmed BRC, stage I to IIIa
- ER positive /HER2 negative
- Application of adjuvant hormone therapy with aromase inhibitors: 6 to 30 months
- Body mass index from 20 to 34.9 kg/m 2
- Able to understand the requirements of the study and provide written information consent
Exclusion Criteria:
- Metastatic or locally advanced disease
- HER2-positive tumors
- Presence of other malignant or serious chronic diseases
- Active infections
- Previous stroke or heart attack,
- Rheumatoid arthritis and other types of autoimmune diseases
- Presence of a significant neurological deficit
- Dementia
- Allergy to the ingredients of the dietary preparation or to fish, fish oil and nuts fruits.
- Allergies to evening primrose oil or other oils containing gamma-linolenic acid (borage, black currant)
- Use of lipid-lowering drugs (statins, Normolip)
- Current use of warfarin or other anticoagulants
- Corticosteroid therapy for the last month
- Use of dietary supplements based on fish oil, evening primrose, and flaxseed oils, omega 3-6-9 fatty acids, multivitamins with added omega-3 of fatty acids 3 months before the start of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AI Diet
Personalised diet rich in whole grains high in fibres, vegetables (particularly leafy greens and tomatoes), polyphenol-rich fruits (berries), and n-3 FAs foods (fatty fish, nuts, seeds and oils)
|
diet rich in whole grains, healthy oils and polyphenols,
|
|
Active Comparator: Supplements
2 gel capsules/d of fish oil (FO) + 3 gel capsules/d of evening primrose oil (EPO), containing 600 mg EPA, 400 mg DHA and 351 mg GLA + Standard diet: 55% carbohydrate, 15% protein and 30% fats
|
Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
|
|
Placebo Comparator: Placebo
Standard diet: 55% carbohydrate, 15% protein and 30% fats + placebo capsules
|
Placebo caps with standard diet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nutritional status
Time Frame: baseline, 4 months, 1 year
|
assessed through blood cells count
|
baseline, 4 months, 1 year
|
|
Nutritional status
Time Frame: baseline, 4 months, 1 year
|
assessed through body mass index-BMI
|
baseline, 4 months, 1 year
|
|
Nutritional status
Time Frame: baseline, 4 months, 1 year
|
assessed through body composition- lean tissue, fat tissue and body water (in kg)
|
baseline, 4 months, 1 year
|
|
Clinical outcome
Time Frame: baseline, 4 months, 1 year
|
assessed through Laboratory analyses including BRC marker CA 15-3
|
baseline, 4 months, 1 year
|
|
Clinical outcome
Time Frame: baseline, 4 months, 1 year
|
assessed through potential complications and side-effects
|
baseline, 4 months, 1 year
|
|
Changes in Quality of life
Time Frame: baseline, 4 months
|
assessed through the questionnaires FACT ES.
The response scale is 5 point Likert-type scale (0- not at all, 4- very much).
|
baseline, 4 months
|
|
Changes in Quality of life
Time Frame: baseline, 4 months
|
assessed through the questionnaires EORTC QLQ-C30.
All items are scored on a 4-point categorical scale ranging from 1- not at al to 4- very much, except the two items of the global quality of life which use a modified 7-point linear analogue scale ranging from 1- very bad to 7- excellent.
|
baseline, 4 months
|
|
Changes in Quality of life
Time Frame: baseline, 4 months
|
assessed through the questionnaires QLQ-BR23.
All items are scored on a 4-point categorical scale ranging from 1- not at al to 4- very much.
|
baseline, 4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inflammatory status
Time Frame: baseline, 4 months,
|
levels of inflammatory markers IL-6, IL-8, IL-10 and TNF-α
|
baseline, 4 months,
|
|
Redox status
Time Frame: baseline, 4 months,
|
total antioxidant status (TAS), total advanced oxidation protein products (AOPP), total oxidant status (TOS), all in micromol/L
|
baseline, 4 months,
|
|
Redox status
Time Frame: baseline, 4 months,
|
superoxide dismutase (SOD)
|
baseline, 4 months,
|
|
Redox status
Time Frame: baseline, 4 months,
|
thiobarbituric acid reactive substances (TBARS)
|
baseline, 4 months,
|
|
leptin and adiponectin
Time Frame: baseline, 4 months
|
plasma levels of leptin and adiponectin
|
baseline, 4 months
|
|
Fatty acid status
Time Frame: baseline, 4 months
|
Fatty acid mol% of plasma phospholipids
|
baseline, 4 months
|
|
Lipidomic analysis
Time Frame: baseline, 4 months
|
LC-MS lipids analysis
|
baseline, 4 months
|
|
FADS1/FADS2
Time Frame: baseline
|
Polymorphism of FADS1/FADS2 genes to test if the patient is homozygote with major or minor alleles or heterozygote for rs174537, rs174576 and rs174602
|
baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AID5050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.